News articles about Pfizer (NYSE:PFE) have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies positive and negative news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Pfizer earned a coverage optimism score of 0.18 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 46.413350427464 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the media stories that may have impacted Accern Sentiment Analysis’s scoring:
- Pfizer, Inc. (PFE) Sees Large Decrease in Short Interest (americanbankingnews.com)
- How to Know if You Should Buy, Sell or Hold Pfizer Inc. (investorplace.com)
- Before Follow You need to Know about Pfizer Inc. (PFE) – Wall Street Morning (wallstreetmorning.com)
- Analyst: Is The Street Ignoring Pfizer And Its Upcoming Catalysts? – Benzinga (benzinga.com)
- Pfizer (PFE) Names Albert Bourla as COO – StreetInsider.com – StreetInsider.com (streetinsider.com)
Several brokerages have recently commented on PFE. Berenberg Bank restated a “hold” rating and set a $36.00 price objective (down from $39.00) on shares of Pfizer in a research report on Tuesday, August 15th. BidaskClub upgraded shares of Pfizer from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 5th. BMO Capital Markets restated a “buy” rating and set a $39.00 price objective on shares of Pfizer in a research report on Friday, November 10th. UBS AG restated a “buy” rating and set a $38.00 price objective on shares of Pfizer in a research report on Monday, July 31st. Finally, Cowen and Company set a $43.00 price objective on shares of Pfizer and gave the company a “buy” rating in a research report on Monday, August 14th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and twelve have issued a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $38.48.
Shares of Pfizer (PFE) opened at $35.38 on Wednesday. Pfizer has a fifty-two week low of $30.51 and a fifty-two week high of $36.78. The company has a quick ratio of 1.15, a current ratio of 1.43 and a debt-to-equity ratio of 0.56. The firm has a market cap of $210,220.00, a PE ratio of 14.07, a PEG ratio of 2.49 and a beta of 1.01.
Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, topping analysts’ consensus estimates of $0.65 by $0.02. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The firm had revenue of $13.17 billion for the quarter, compared to the consensus estimate of $13.17 billion. During the same period in the previous year, the firm posted $0.61 EPS. The business’s quarterly revenue was up .9% on a year-over-year basis. research analysts anticipate that Pfizer will post 2.59 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, December 1st. Stockholders of record on Friday, November 10th will be issued a $0.32 dividend. The ex-dividend date of this dividend is Thursday, November 9th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.62%. Pfizer’s dividend payout ratio (DPR) is presently 78.53%.
In related news, CEO Ian C. Read sold 197,168 shares of Pfizer stock in a transaction dated Thursday, August 31st. The shares were sold at an average price of $34.00, for a total transaction of $6,703,712.00. Following the completion of the transaction, the chief executive officer now directly owns 580,318 shares of the company’s stock, valued at approximately $19,730,812. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Alexander R. Mackenzie sold 7,350 shares of Pfizer stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $35.65, for a total transaction of $262,027.50. Following the transaction, the executive vice president now directly owns 117,432 shares of the company’s stock, valued at $4,186,450.80. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 374,621 shares of company stock worth $12,796,098. Insiders own 0.06% of the company’s stock.
TRADEMARK VIOLATION WARNING: This news story was first posted by Stock Observer and is the property of of Stock Observer. If you are viewing this news story on another site, it was copied illegally and reposted in violation of international copyright & trademark law. The correct version of this news story can be read at https://www.thestockobserver.com/2017/11/15/pfizer-pfe-earns-daily-news-impact-score-of-0-18.html.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.